<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301807</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0733</org_study_id>
    <secondary_id>NCI-2018-01845</secondary_id>
    <secondary_id>2010-0733</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01301807</nct_id>
  </id_info>
  <brief_title>Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients With Relapsed/Refractory Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/Ib trial studies the side effects and best dose of panobinostat and carfilzomib
      in treating participants with multiple myeloma that has come back or that isn't responding to
      treatment. Carfilzomib keeps cancer cells from repairing themselves. If the cancer cells
      cannot repair themselves, they may die. Panobinostat may stop the growth of cancer cells by
      blocking some of the enzymes needed for cell growth. Giving panobinostat and carfilzomib may
      work better in treating participants with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum recommended dose (MRD) of the combination of carfilzomib and
      panobinostat in patients with relapsed/refractory multiple myeloma (RRMM). (Phase I) II. To
      determine the overall response rate (stable disease [SD], minimal response [MR], partial
      response [PR], very good partial response [VGPR], near complete response/complete response
      [nCR/CR] of the combination. (Phase Ib)

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate (ORR), stable disease (SD), minimal response (MR),
      partial response (PR), very good partial response (VGPR), near complete response/complete
      response (nCR/CR). (Phase I) II. To determine the time to progression (TTP). (Phase I and Ib)
      III. To determine the progression free survival (PFS). (Phase I and Ib) IV. To determine the
      time to best response. (Phase I and Ib) V. To determine time to next therapy. (Phase I and
      Ib) VI. To determine duration of response. (Phase I and Ib) VII. To determine the overall
      response rate (SD, MR, PR, VGPR, nCR/CR) of the combination. (Phase Ib) VIII. To assess the
      safety of the combination. (Phase Ib)

      OUTLINE: This is a phase I and Ib dose escalation study.

      Participants receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9, 15,
      and 16 and panobinostat orally (PO) once daily (QD) on days 1, 3, 5, 8, 10, and 12 of each
      course. Courses repeat every 28 days for up to 8 courses in the absence of disease
      progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib
      IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each
      course. If the disease becomes worse, participants can receive carfilzomib on the original
      dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).

      After completion of study treatment, participants are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2011</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of the drug combination</measure>
    <time_frame>At 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>30 days after the last dose is given</time_frame>
    <description>Will use Kaplan-Meier methods appropriate for survival analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Non-Secretory Plasma Cell Myeloma</condition>
  <condition>Plasmacytosis</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (carfilzomib, panobinostat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (carfilzomib, panobinostat)</arm_group_label>
    <other_name>Kyprolis</other_name>
    <other_name>PR-171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (carfilzomib, panobinostat)</arm_group_label>
    <other_name>Faridak</other_name>
    <other_name>Farydak</other_name>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed/refractory MM with failure to at least two lines of MM treatment which must
             include at least one IMiD (thalidomide, lenalidomide) and proteosome inhibitor
             (bortezomib) and measurable levels of myeloma paraprotein in serum ( &gt;/= 0.5 g/dl),
             urine ( &gt;/= 0.2 g excreted in a 24-hour collection sample), or abnormal free light
             chain (FLC) ratio. Oligo or non secretory myeloma patients may be included, if there
             is measurable plasmacytosis in the bone marrow biopsy or measurable extramedullary
             disease.

          2. Male or female patients aged &gt;/= 18 years old

          3. Ability to provide written informed consent obtained prior to participation in the
             study and any related procedures being performed

          4. Patients must meet the following laboratory criteria within 28 days of starting
             therapy: * Absolute neutrophil count (ANC) &gt;/= 1.0 x 10^9/L * Hemoglobin &gt;/= 8 g/dl (
             transfusion are permitted) * Platelet count &gt; 70,000 cells/mm^3 for patients with &lt;
             50% of bone marrow plasma cells or platelet count &gt; 25,000 cells/mm^3 for patients in
             whom &gt; 50% of the bone marrow nucleated cells were plasma cells * aspartate
             aminotransferase (AST) and Alanine aminotranferease (ALT) &lt;/= 2.5 x ULN * Serum
             bilirubin &lt;/= 2 x ULN

          5. ECOG Performance Status of &lt;/= 2

          6. Creatinine clearance (CrCl) &gt;/= 30 mL/minute within 28 days prior to registration,
             either measured or calculated using a standard formula (eg, Cockcroft and Gault)

          7. Multiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF &gt;/=
             45%.

          8. Female patients who: Are postmenopausal for at least 1 year before the screening
             visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to
             practice 2 effective methods of contraception, at the same time, from the time of
             signing the informed consent through 30 days after the last dose of study drug, or
             agree to completely abstain from heterosexual intercourse. Male patients, even if
             surgically sterilized (ie, status postvasectomy), who: Agree to practice effective
             barrier contraception during the entire study treatment period and through 30 days
             after the last dose of study drug, OR Agree to completely abstain from heterosexual
             intercourse.

        Exclusion Criteria:

          1. Valproic acid for the treatment of cancer

          2. Patients who will need valproic acid for any medical condition during the study or
             within 5 days prior to first panobinostat treatment

          3. Impaired cardiac function or clinically significant cardiac diseases, including any
             one of the following: * History or presence of sustained ventricular tachyarrhythmia.
             (Patients with a history of atrial arrhythmia are eligible) * Any history of
             ventricular fibrillation or torsade de pointes * Bradycardia defined as heart rate
             (HR)&lt; 50 bpm. Patients with pacemakers are eligible if HR &gt;/= 50 bpm. * Screening
             electrocardiogram (ECG) with a corrected QT interval (QTc) or QTcF &gt; 450 msec * Right
             bundle branch block + left anterior hemiblock (bifascicular block) * Patients with
             myocardial infarction or unstable angina &lt;/= 6 months prior to starting study drug *
             Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF) New
             York Heart Association (NYHA) class III or IV , uncontrolled hypertension, history of
             labile hypertension, or history of poor compliance with an antihypertensive regimen)

          4. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of panobinostat

          5. Patients with diarrhea &gt; Common Terminology Criteria for Adverse Events (CTCAE) grade
             2

          6. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
             diabetes or active or uncontrolled infection) including abnormal laboratory values,
             that could cause unacceptable safety risks or compromise compliance with the protocol

          7. Patients using medications that have a relative risk of prolonging the QT interval or
             inducing torsade de pointes if treatment cannot be discontinued or switched to a
             different medication prior to starting study drug

          8. Patients who have received chemotherapy within &lt;/= 2 weeks by time of cycle 1 day 1 of
             therapy on trial ; or radiation therapy to &gt; 30% of marrow-bearing bone within 2 weeks
             prior to starting study treatment; or who have not yet recovered from side effects of
             such therapies.

          9. Female patients who are lactating or have a positive serum or urine pregnancy test
             during the Screening period.

         10. Patients with any significant history of non-compliance to medical regimens or
             unwilling or unable to comply with the instructions given to him/her by the study
             staff.

         11. Known history of allergy to CaptisolÂ® (a cyclodextrin derivative used to solubilize
             carfilzomib)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Orlowski</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>December 28, 2019</last_update_submitted>
  <last_update_submitted_qc>December 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

